3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
5
Recruiting
2
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Head & Neck
3
Gastrointestinal
3
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
30
Rituximab
23
zanubrutinib
18
fludarabine
14
Vincristine
14
venetoclax
13
Prednisone
13
blinatumomab
12
Magnetic Resonance Spectroscopy
12
Specimen Handling
11
Doxorubicin
11
obinutuzumab
10
Bendamustine Hydrochloride
10
Lenalidomide
9
Dexamethasone
8
polatuzumab vedotin
7
glofitamab
7
Methotrexate
7
Radiotherapy
6
Prednisolone
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Cytarabine
6
Biopsy
6
pirtobrutinib
5
pegaspargase
5
Immunotherapy, Adoptive
5
tislelizumab
4
tafasitamab
4
selinexor
4
orelabrutinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
trametinib
×
Lymphoid
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled